<DOC>
	<DOC>NCT00452504</DOC>
	<brief_summary>This is a first-in-humans study of SRA-444. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SRA-444 (SR formulation) after administration of ascending single oral doses to healthy adult subjects.</brief_summary>
	<brief_title>Single Ascending Dose Study of SRA-444 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criteria: Healthy men or women of nonchildbearing potential aged 18 to 50 years, Body mass index in the range of 18 to 30 kg/m2 and body weight ≥50 kg. Exclusion criteria: Family history of sudden death and/or QT prolongation. An automatic ECG corrected QT (QTc) interval reading at screening &gt;450 ms and &gt;470 ms for male and female subjects, respectively. Sinus bradycardia at screening, defined as a resting heart rate ≤45 bpm. Resting supine blood pressure at screening &lt;110 mm Hg (systolic) and/or &lt;60 mm Hg (diastolic).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>